Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron Pharmaceuticals Inc. closed 43.47% below its 52-week high of $1,211.20, which the company achieved on August 27th.

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...